SILO PHARMA, INC.: 10-Q filed 2012-08-01

Name: SILO PHARMA, INC.: 10-Q filed 2012-08-01
Creator: SILO PHARMA, INC.

What SILO PHARMA, INC. reported in its quarterly report filed 2012-08-01 (fiscal Q2 2012): 15 published measures, 46 facts as tagged in accession 0001213900-12-004111.

This filing

Form: 10-Q (quarterly report)
Filed: 2012-08-01
Fiscal period: fiscal Q2 2012
Accession: 0001213900-12-004111 on SEC EDGAR

Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All SILO PHARMA, INC. filings.

Reported measures

Total assets

Resources recognized on the balance sheet. Book assets are not the market value of the business.

Period	Value	Unit	Days
At 2012-06-30	813	USD
At 2011-12-31	1,752	USD

Total liabilities

Recognized obligations at the reporting date. The definition and scope differ from interest-bearing debt.

Period	Value	Unit	Days
At 2012-06-30	21,268	USD
At 2011-12-31	3,500	USD

Cash and cash equivalents

Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.

Period	Value	Unit
At 2012-06-30	813	USD
At 2011-12-31	1,752	USD
At 2011-06-30	25,804	USD
At 2010-12-31	47,480	USD
At 2010-07-12	0	USD

Operating cash flow

Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.

Period	Value	Unit	Days
2012-01-01 to 2012-06-30	-15,939	USD	182
2010-07-13 to 2012-06-30	-65,747	USD	719
2011-01-01 to 2011-06-30	-22,251	USD	181

Financing cash flow

Net cash from financing activities, including borrowing, repayments and transactions with owners. A positive amount does not establish operating profitability.

Period	Value	Unit	Days
2012-01-01 to 2012-06-30	15,000	USD	182
2010-07-13 to 2012-06-30	66,560	USD	719
2011-01-01 to 2011-06-30	575	USD	181

Share-based compensation expense

Reported noncash expense for share-based payment arrangements. Noncash treatment does not mean the awards have no economic cost to shareholders.

Period	Value	Unit	Days
2012-01-01 to 2012-06-30	0	USD	182
2010-07-13 to 2012-06-30	1,075,000	USD	719
2011-01-01 to 2011-06-30	0	USD	181

Current assets

Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.

Period	Value	Unit	Days
At 2012-06-30	813	USD
At 2011-12-31	1,752	USD

Current liabilities

Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.

Period	Value	Unit	Days
At 2012-06-30	6,268	USD
At 2011-12-31	3,500	USD

Current accounts payable

Current amounts owed to suppliers for goods and services received. This is one component of current liabilities, not all accrued obligations.

Period	Value	Unit	Days
At 2012-06-30	6,268	USD
At 2011-12-31	3,500	USD

Common shares outstanding

Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.

Period	Value	Unit	Days
At 2012-06-30	30,631,200	shares
At 2011-12-31	30,631,200	shares

Additional paid-in capital

Capital contributed above par value under this concept. It records historical contributions, not the current value of the equity or cash on hand.

Period	Value	Unit	Days
At 2012-06-30	1,123,497	USD
At 2011-12-31	1,123,497	USD

Total equity including noncontrolling interests

Equity including the portion attributable to noncontrolling interests. It is larger than or equal to parent stockholders equity and is not market capitalization.

Period	Value	Unit
At 2012-06-30	-20,455	USD
At 2011-12-31	-1,748	USD
At 2010-12-31	47,480	USD

Profit or loss including noncontrolling interests

Net income or loss including the portion attributable to noncontrolling interests. It can differ from the net income attributable to the parent that per-share figures use.

Period	Value	Unit	Days
2012-04-01 to 2012-06-30	-5,668	USD	91
2012-01-01 to 2012-06-30	-18,707	USD	182
2010-07-13 to 2012-06-30	-1,147,015	USD	719
2011-01-01 to 2011-12-31	-49,803	USD	365
2011-04-01 to 2011-06-30	-13,853	USD	91
2011-01-01 to 2011-06-30	-25,751	USD	181
2010-07-13 to 2010-12-31	-1,078,505	USD	172

General and administrative expense

General and administrative costs reported under this concept, separate from selling expense. Filers group overhead differently, so compare presentation before comparing companies.

Period	Value	Unit	Days
2012-04-01 to 2012-06-30	5,668	USD	91
2012-01-01 to 2012-06-30	18,707	USD	182
2010-07-13 to 2012-06-30	1,147,015	USD	719
2011-04-01 to 2011-06-30	13,853	USD	91
2011-01-01 to 2011-06-30	25,751	USD	181

Proceeds from issuing common stock

Cash received from issuing common stock during the period. It is gross of costs only where the filer reports it so, and it does not include noncash issuances.

Period	Value	Unit	Days
2012-01-01 to 2012-06-30	0	USD	182
2010-07-13 to 2012-06-30	51,560	USD	719
2011-01-01 to 2011-06-30	575	USD	181

Inspect the source

Entity: SILO PHARMA, INC. / CIK 0001514183
Captured: 2026-09-20T09:13:20.337Z
SEC response SHA-256: b55b01ff5b31c52a933a54029f5fe837eae02333bd43de16acad37f51e3b67db

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

Read the published dataset with Python

import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0001514183.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))